APP, in conjunction with the FDA, began importing Fresenius Propoven 1% in late 2009 but stopped in Feb. 2010 when the initial supply ran out, according to the letter.
Effective immediate, APP, which is the only company authorized to import Fresenius Propoven 1%, will begin importing the following products:
- DIPRIVAN (20-mL, 50-MI and 100-mL vials)
- APP Propofol 1% (20-mL, 50-MI and 100-mL vials)
- Fresenius Propoven 1% (20-mL, 50-MI and 100-mL vials)
The letter also notes some important difference between U.S.-manufactured propofol and international Fresenius Propoven 1%, including contraindication in patients with peanut and soy allergies. For complete information on the difference, please refer to the APP’s letter.
Read APP’s letter on Fresenius Propoven 1% (pdf).
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.